Stilla Technologies raises €20 million ($22 million) in Series B round that brings in new investor, TUS-Holdings, alongside existing ones
Stilla Technologies raises €20 million ($22 million) in Series B round that brings in new investor, TUS-Holdings, alongside existing ones
02/14/20, 12:18 AM
Location
parisMoney raised
€20 million
Industry
biotechnology
science and engineering
data and analytics
health care
software
Round Type
series b
Stilla Technologies, a leading provider of pioneering digital PCR (dPCR) solutions for high-precision genetic analysis, has just raised €20 million ($22 million) in a Series B funding round that brought in a new investor, the Chinese group TUS-Holdings, alongside the participation of existing investors Illumina Ventures, Kurma Partners, LBO France, Paris Saclay Seed Funds, BNP Paribas Développement and Idinvest Partners.
Company Info
Location
paris, ile de france, france
Additional Info
The Naica System is a highly sensitive digital PCR solution that runs on the company's next-generation genetic testing and nucleic acid quantification technology, Crystal Digital™ PCR. The Naica System is uniquely capable of characterizing multiple types of nucleic acids with its three-color detection capability. Its ease of use and fastest time to results — in two hours and 30 minutes —set this innovative technology apart on the digital PCR market. The Naica System supports a wide range of genetic tests and molecular biology assays — including liquid biopsy tests for cancer diagnostics, viral load quantification, pre-natal testing, and GMO detection. Overall, the Naica System's superior performances make it a preferred technology for precision medicine research and therapeutic monitoring.